BDSI Announces Director Resignations; Donald Ferguson and Alan Pearce Resign So That Company Can Comply with Nasdaq Independence
16 Settembre 2005 - 10:30PM
Business Wire
BioDelivery Sciences International, Inc. (NASDAQ: BDSI, BDSIW)
announced today that, effective September 15, 2005, Donald Ferguson
and Alan Pearce have resigned from the company's board of
directors. The resignations were undertaken so that BDSI could
maintain the independent director requirement for continued listing
on the Nasdaq Stock Market. On September 15, 2005, the company
received a written notification from the staff of the Nasdaq Stock
Market indicating the staff's view that Mr. Ferguson is not
"independent" under NASD Rule 4200(a)(15) and that, therefore,
BDSI's board of directors was not comprised of a majority of
independent directors as required by NASD Rule 4350(c)(1). As a
result of the staff's determination, Mr. Ferguson and Mr. Pearce,
who is not independent, have resigned from the board of directors.
BDSI's board of directors is now comprised on seven members, four
of whom are "independent" under NASD rules. BDSI has notified the
Nasdaq staff of this action and, as a result, the staff has
provided BDSI with a written notification that the company has
regained compliance with NASD rules and that this matter is closed.
The company also announced that in their respective resignation
letters to BDSI, both Mr. Ferguson and Mr. Pearce indicated that
their resignations did not result from any disagreement between
them and BDSI, its management or its board of directors.
BioDelivery Sciences International, Inc. is a specialty
biopharmaceutical company that is exploiting its licensed and
patented drug delivery technologies to develop and commercialize,
either on its own or in partnerships with third parties,
clinically-significant new formulations of proven therapeutics
targeted at "acute" treatment opportunities such as pain, anxiety,
nausea and vomiting and infections. The company's drug delivery
technologies include: (i) the patented Bioral(R) nanocochleate
technology, designed for a potentially broad base of applications,
and (ii) the patented BEMA(TM) (transmucosal or mouth) drug
delivery technology. The company's headquarters are located in
Morrisville, North Carolina and its principal laboratory is located
in Newark, New Jersey. Note: Except for the historical information
contained herein, this press release contains, among other things,
certain forward-looking statements, within the meaning of the
Private Securities Litigation Reform Act of 1995, that involve
risks and uncertainties. Such statement may include, without
limitation, statements with respect to the Company's plans,
objectives, expectations and intentions and other statements
identified by words such as "may," "could," "would," "should,"
"believes," "expects," "anticipates," "estimates," "intends,"
"plans" or similar expressions. These statements are based upon the
current beliefs and expectations of the Company's management and
are subject to significant risks and uncertainties, including those
detailed in the Company's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in the
forward-looking statements. These forward-looking statements
involve certain risks and uncertainties that are subject to change
based on various factors (many of which are beyond the Company's
control). L.G. Zangani, LLC provides financial public relations
service to the Company. As such L.G. Zangani, LLC and/or its
officers, agents and employees, receives remuneration for public
relations and or other services in the form of monies, capital
stock in the Company, warrants or options to purchase capital in
the Company.
Grafico Azioni Biodelivery Sciences International (MM) (NASDAQ:BDSIW)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Biodelivery Sciences International (MM) (NASDAQ:BDSIW)
Storico
Da Set 2023 a Set 2024